Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

Scientists could also use cloned stem cell lines to create new diagnostic tests or tools for drug discovery. “We have nothing in the genetic tool box to diagnose what’s happening early on in a disease,” says Renee A. Reijo Pera, codirector of the human stem cell biology program at the University of California, San Francisco. “Embryonic stem cells let you go back to day-one of the disease.”

In Alzheimer’s disease, for example, the brain is significantly damaged by the time the patient sees a doctor. To search for early signs of the disorder, scientists could generate stem cells using DNA from an Alzheimer’s patient, then coax those cells to differentiate into neurons, monitoring the cells for specific proteins or other molecular changes that are different from neurons derived from healthy embryonic stem cells. The same approach might work with cancer, which is characterized by a series of harmful genetic changes. “We want to know what’s the earliest you can detect differences in disease cells,” says Reijo Pera, who is planning a new research program in human therapeutic cloning.

Scientists also hope that cloning stem cells will bring the field one step closer to a major goal of stem cell biology: to take an adult cell and turn it back into a stem cell without the use of human eggs. This feat would ultimately circumvent the biggest ethical concerns surrounding therapeutic cloning – the creation and destruction of a human embryo. Scientists hope that if they can understand how an egg “reprograms” an adult cell into its undifferentiated state, they can eventually eliminate the need for human eggs and embryos.

0 comments about this story. Start the discussion »

Tagged: Biomedicine

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me